Also, GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists might improve the course of MASLD (105, 106), which in turn can decrease the risk of diabetes mellitus, subsequently reducing the incidence of stroke (107). The gene discussed is GLP1R; the disease is Stroke.